Monthly Archives: April 2015

Milestone payments are an important risk-sharing component in today’s biopharma deal-making toolbox. As it’s a topic I’ve explored in the past (here, here), it’s an opportune time to revisit the stats for how they have performed recently. These contingent value transfers

This blog was written by Michael Gladstone, Principal at Atlas Venture, as part of the “From the Trenches” feature of LifeSciVC. “A big asset of VC’s is pattern recognition. It is also often our biggest liability.”  An apt observation tweeted by

This blog was written by Mike Gilman, CEO of Padlock Therapeutics and Atlas EIR, as part of the “From the Trenches” feature of LifeSciVC. Padlock Therapeutics is my second startup, and it’s not nearly as scary as the first one. Not

Biotech venture funding metrics continue at historic highs, highlighting that the robust financing environment in the public markets continues to fuel the private markets as well. Last week the quarterly Thomson Reuters data on venture capital funding came out via

Earlier this week Atlas Venture closed Fund X at $280M, completing our transition to a biotech-only venture firm. After announcing the split of our life science and technology franchises in October 2014 (here), we embarked on the hard work of

This blog was written by Bill Marshall, CEO of miRagen Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. The opportunity to use nucleic acids as therapeutic agents is extremely exciting. Creating drugs that affect protein targets that are